Medline Inc. (MDLN) stock
Close on Nov 18, 2026Market cap $51.48BP/E –Yield –
Earnings
Medline's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Medline's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 26, 2026 | Nov 4, 2026before the open | $7.90B | – | $0.22 | $0.44 | Release |
| Q2 FY2026ended Jun 27, 2026 | Aug 5, 2026before the open | $7.70B | – | $0.07 | $0.50 | Release |
| Q1 FY2026ended Mar 28, 2026 | May 6, 2026before the open | $7.40B | – | $0.16 | $0.33 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026before the open | $7.80B | – | -$0.01 | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Medline's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Organic Salesnon-GAAP | FY2026 | +10% – +10.5% | – | New | Nov 4, 2026 |
| Organic Salesnon-GAAP | FY2026 | +9% – +10% | +8.5% – +9.5% | Raised | Aug 5, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $3.30B – $3.40B | – | New | Nov 4, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $3.30B – $3.40B | $3.50B – $3.60B | Lowered | Aug 5, 2026 |
Guidance history
Every forecast Medline put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | Adjusted EBITDA | FY2026 | $3.30B – $3.40B | New |
| Nov 4, 2026 | Organic Sales | FY2026 | +10% – +10.5% | New |
| Aug 5, 2026 | Adjusted EBITDA | FY2026 | $3.30B – $3.40B | Lowered |
| Aug 5, 2026 | Organic Sales | FY2026 | +9% – +10% | Raised |
| May 6, 2026 | Adjusted EBITDA | FY2026 | $3.50B – $3.60B | Reaffirmed |
| May 6, 2026 | Organic Sales growth | FY2026 | +8.5% – +9.5% | Raised |
| Feb 25, 2026 | Adjusted EBITDA | FY2026 | $3.50B – $3.60B | New |
| Feb 25, 2026 | Organic Sales | FY2026 | +8% – +9% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Medline filed with the SEC as exhibits to Form 8-K or 6-K
See a number that looks wrong?